MazzaferriEL, KloosRT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab, 2001; 86(4):1447–1463; doi: 10.1210/jcem.86.4.7407
2.
NixonIJ, WhitcherMM, PalmerFL, et al.The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. Thyroid, 2012; 22(9):884–889; doi: 10.1089/thy.2011.0535
3.
DuranteC, HaddyN, BaudinE, et al.Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. J Clin Endocrinol Metab, 2006; 91(8):2892–2899; doi: 10.1210/jc.2005-2838
4.
HaugenBR, AlexanderEK, BibleKC, et al.2015 American Thyroid Association Management Guidelines for Adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid nodules and differentiated thyroid cancer. Thyroid, 2016; 26(1):1–133; doi: 10.1089/thy.2015.0020
5.
GiovanellaL, van NostrandD. Advanced differentiated thyroid cancer: When to stop radioiodine?. Q J Nucl Med Mol Imaging, 2019; 63(3):267–270; doi: 10.23736/S1824-4785.19.03191-1
6.
Van NostrandD.Radioiodine refractory differentiated thyroid cancer: Time to update the classifications. Thyroid, 2018; 28(9):1083–1093; doi: 10.1089/thy.2018.0048
7.
LandaI, IbrahimpasicT, BoucaiL, et al.Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest, 2016; 126(3):1052–1066; doi: 10.1172/JCI85271
8.
IbrahimpasicT, XuB, LandaI, et al.Genomic alterations in fatal forms of non-anaplastic thyroid cancer: Identification of MED12 and RBM10 as novel thyroid cancer genes associated with tumor virulence. Clin Cancer Res, 2017; 23(19):5970–5980; doi: 10.1158/1078-0432.CCR-17-1183
9.
PozdeyevN, GayLM, SokolES, et al.Genetic analysis of 779 Advanced differentiated and anaplastic thyroid cancers. Clin Cancer Res, 2018; 24(13):3059–3068; doi: 10.1158/1078-0432.CCR-18-0373
10.
Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell, 2014; 159(3):676–690; doi: 10.1016/j.cell.2014.09.050
11.
XuB, GhosseinR. Genomic landscape of poorly differentiated and anaplastic thyroid carcinoma. Endocr Pathol, 2016; 27(3):205–212;doi: 10.1007/s12022-016-9445-4
12.
GerberTS, SchadA, HartmannN, et al.Targeted next-generation sequencing of cancer genes in poorly differentiated thyroid cancer. Endocr Connect, 2018; 7(1):47–55; doi: 10.1530/EC-17-0290
13.
DuanH, LiY, HuP, et al.Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing. Histopathology, 2019; 75(6):890–899; doi: 10.1111/his.13942
14.
MaLX, Espin-GarciaO, BedardPL, et al.Clinical application of next-generation sequencing in advanced thyroid cancers. Thyroid, 2022; 32(6):657–666; doi: 10.1089/thy.2021.0542
15.
YangX, LiJ, LiX, et al.TERT promoter mutation predicts radioiodine-refractory character in distant metastatic differentiated thyroid cancer. J Nucl Med, 2017; 58(2):258–265; doi: 10.2967/jnumed.116.180240
16.
LeeSE, HwangTS, ChoiYL, et al.Prognostic significance of TERT promoter mutations in papillary thyroid carcinomas in a BRAF(V600E) mutation-prevalent population. Thyroid, 2016; 26(7):901–910; doi: 10.1089/thy.2015.0488
17.
LiuX, BishopJ, ShanY, et al.Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer, 2013; 20(4):603–610; doi: 10.1530/ERC-13-0210
18.
LiuJ, LiuR, ShenX, et al.The Genetic Duet of BRAF V600E and TERT promoter mutations robustly predicts loss of radioiodine avidity in recurrent papillary thyroid cancer. J Nucl Med, 2020; 61(2):177–182; doi: 10.2967/jnumed.119.227652
19.
MoonS, SongYS, KimYA, et al.Effects of coexistent BRAF(V600E) and TERT promoter mutations on poor clinical outcomes in papillary thyroid cancer: A meta-analysis. Thyroid, 2017; 27(5):651–660; doi: 10.1089/thy.2016.0350
20.
LiuX, QuS, LiuR, et al.TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab, 2014; 99(6):E1130–E1136; doi: 10.1210/jc.2013-4048
21.
VuongHG, AltibiAMA, DuongUNP, et al.Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma—A meta-analysis. Clin Endocrinol (Oxf), 2017; 87(5):411–417; doi: 10.1111/cen.13413
22.
GarganoSM, BadjatiaN, NikolausY, et al.Characterization and clinical significance of EIF1AX mutations and co-mutations in cytologically indeterminate thyroid nodules: A 5-year retrospective analysis. Acta Med Acad, 2021; 50(1):4–12; doi: 10.5644/ama2006-124.322
23.
Karslioglu FrenchE, NikitskiAV, YipL, et al.Clinicopathological features and outcomes of thyroid nodules with EIF1AX mutations. Endocr Relat Cancer, 2022; 29(8):467–473; doi: 10.1530/ERC-22-0041
24.
JinM, SongDE, AhnJ, et al.Genetic profiles of aggressive variants of papillary thyroid carcinomas. Cancers (Basel), 2021; 13(4):892; doi: 10.3390/cancers13040892
25.
HuangS, HolzelM, KnijnenburgT, et al.MED12 controls the response to multiple cancer drugs through regulation of TGF-beta receptor signaling. Cell, 2012; 151(5):937–950; doi: 10.1016/j.cell.2012.10.035
26.
ZhangS, O'ReganR, XuW. The emerging role of mediator complex subunit 12 in tumorigenesis and response to chemotherapeutics. Cancer, 2020; 126(5):939–948; doi: 10.1002/cncr.32672
27.
KampjarviK, KimNH, KeskitaloS, et al.Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms. Prostate, 2016; 76(1):22–31; doi: 10.1002/pros.23092
28.
MiasakiFY, SaitoKC, YamamotoGL, et al.Thyroid and breast cancer in 2 sisters with monoallelic mutations in the ataxia telangiectasia mutated (ATM) gene. J Endocr Soc, 2022; 6(4):bvac026; doi: 10.1210/jendso/bvac026
29.
SongCM, KwonTK, ParkBL, et al.Single nucleotide polymorphisms of ataxia telangiectasia mutated and the risk of papillary thyroid carcinoma. Environ Mol Mutagen, 2015; 56(1):70–76; doi: 10.1002/em.21898
30.
GuY, YuY, AiL, et al.Association of the ATM gene polymorphisms with papillary thyroid cancer. Endocrine, 2014; 45(3):454–461; doi: 10.1007/s12020-013-0020-1
31.
TchekmedyianV, DunnL, ShermanE, et al.Enhancing radioiodine incorporation in BRAF-mutant, radioiodine-refractory thyroid cancers with vemurafenib and the anti-ErbB3 monoclonal antibody CDX-3379: Results of a pilot clinical trial. Thyroid, 2022; 32(3):273–282; doi: 10.1089/thy.2021.0565
32.
SaqcenaM, Leandro-GarciaLJ, MaagJLV, et al.SWI/SNF complex mutations promote thyroid tumor progression and insensitivity to redifferentiation therapies. Cancer Discov, 2021; 11(5):1158–1175; doi: 10.1158/2159-8290.CD-20-0735
33.
BroseMS, NuttingCM, JarzabB, et al.Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 3 trial. Lancet, 2014; 384(9940):319–328; doi: 10.1016/S0140-6736(14)60421-9
34.
YanZ, YangM, LaiCL. Clinical efficacy of lenvatinib for the treatment of radioiodine-refractory thyroid carcinoma: A systematic review and meta-analysis of clinical trials. Clin Endocrinol (Oxf), 2021; 95(3):478–488; doi: 10.1111/cen.14479
35.
SubbiahV, KreitmanRJ, WainbergZA, et al.Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol, 2018; 36(1):7–13; doi: 10.1200/JCO.2017.73.6785
36.
DunnLA, ShermanEJ, BaxiSS, et al.Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers. J Clin Endocrinol Metab, 2019; 104(5):1417–1428; doi: 10.1210/jc.2018-01478
37.
RothenbergSM, McFaddenDG, PalmerEL, et al.Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clin Cancer Res, 2015; 21(5):1028–1035; doi: 10.1158/1078-0432.CCR-14-2915
38.
DhillonAS, HaganS, RathO, et al.MAP kinase signalling pathways in cancer. Oncogene, 2007; 26(22):3279–3290; doi: 10.1038/sj.onc.1210421
39.
FullmerT, CabanillasME, ZafereoM.Novel therapeutics in radioactive iodine-resistant thyroid cancer. Front Endocrinol (Lausanne), 2021; 12:720723; doi: 10.3389/fendo.2021.720723
40.
CaoJ, ZhuX, SunY, et al.The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor curative effect of radioiodine therapy in papillary thyroid cancer. Eur J Nucl Med Mol Imaging, 2022; doi: 10.1007/s00259-022-05820-x
41.
ParvathareddySK, SirajAK, IqbalK, et al.TERT promoter mutations are an independent predictor of distant metastasis in middle Eastern papillary thyroid microcarcinoma. Front Endocrinol (Lausanne), 2022; 13:808298; doi: 10.3389/fendo.2022.808298
42.
MaoJ, HuangX, OklaMK, et al.Risk factors for TERT promoter mutations with papillary thyroid carcinoma patients: A meta-analysis and systematic review. Comput Math Methods Med, 2022;2022:1721526; doi: 10.1155/2022/1721526
43.
PreteA, MatroneA, GambaleC, et al.Poorly differentiated and anaplastic thyroid cancer: Insights into genomics, microenvironment and new drugs. Cancers (Basel), 2021; 13(13); doi: 10.3390/cancers13133200
